| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Iron(III) octaethylporphine chloride does not have a defined pharmacological target as it is a biochemical reagent and synthetic metalloporphyrin. The compound is used as a model compound to study the electronics and magnetism of heme proteins, which play important roles in biological processes such as oxygen transport and metabolism. It is used to reduce oxygen and study heme.
|
|---|---|
| ln Vitro |
In vitro activity of Iron(III) octaethylporphine chloride is assessed in biochemical and catalytic studies. The compound serves as a catalyst in various chemical reactions, particularly in organic synthesis, enhancing reaction rates and selectivity. It is used as an electrocatalyst, a structural benchmark for heme models, and a specialized precursor in photoredox catalysis.
|
| ln Vivo |
No specific in vivo pharmacological activity data have been documented for Iron(III) octaethylporphine chloride as a therapeutic agent. The compound is used in biochemical research as a model for heme proteins and as a catalyst. It is not administered to animals for pharmacological evaluation.
|
| Enzyme Assay |
For non-cellular assays, Iron(III) octaethylporphine chloride is characterized by standard analytical techniques including TLC, NMR, and mass spectrometry to confirm identity and purity. The compound can be evaluated as a catalyst in various chemical reactions. Typical protocols involve dissolving the compound in appropriate organic solvents and analyzing reaction products. Purity: ≥95% (TLC).
|
| Cell Assay |
For in vitro cell-based studies, Iron(III) octaethylporphine chloride is not typically used as a direct test compound. The compound is used in biochemical and catalytic research applications. If handled in a biological laboratory context, standard safety precautions should be taken. The compound should be stored away from moisture.
|
| Animal Protocol |
For in vivo animal studies, Iron(III) octaethylporphine chloride can be formulated using vehicles such as DMSO:PEG300:Tween 80:Saline (10:40:5:45) for intravenous, intraperitoneal, intramuscular, or subcutaneous administration. Dosing solutions should be freshly prepared. Storage: store at 4°C, keep away from moisture.
|
| ADME/Pharmacokinetics |
Iron(III) octaethylporphine chloride has a molecular weight of 624.06 and molecular formula C36H44ClFeN4. Storage: keep away from moisture, store at 4°C. Purity: ≥95% (TLC). The compound is soluble in organic solvents. Appearance: red-colored compound.
|
| Toxicity/Toxicokinetics |
Iron(III) octaethylporphine chloride is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Iron(III) octaethylporphine chloride (CAS 28755-93-3) is also known as chloro(octaethylporphyrinato)iron and Fe(III) octaethylporphine chloride. It is a synthetic metalloporphyrin utilized extensively as an electrocatalyst, a structural benchmark for heme models, and a specialized precursor in photoredox catalysis. The compound is used to study heme proteins and oxygen transport.
|
| Molecular Formula |
C36H44CLFEN4
|
|---|---|
| Molecular Weight |
624.06
|
| Exact Mass |
623.26
|
| CAS # |
28755-93-3
|
| PubChem CID |
57376706
|
| Appearance |
Brown to black solid powder
|
| LogP |
6.821
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
44
|
| Complexity |
787
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCC1=C(CC)C2=CC3=C(CC)C(=C(C=C4C(=C(CC)C(=N4)C=C5C(=C(CC)C(=CC1=N2)[N-]5)CC)CC)[N-]3)CC.[Cl-].[Fe+3]
|
| InChi Key |
SHMMVGOWYAIRHR-UHFFFAOYSA-K
|
| InChi Code |
InChI=1S/C36H46N4.3ClH.Fe/c1-9-22-19-25-20-23-17-18-24(37-23)21-32-26(10-2)29(13-5)36(40(32)16-8)31(15-7)35-28(12-4)27(11-3)34(39-35)30(14-6)33(22)38-25;;;;/h17-21,38H,9-16H2,1-8H3;3*1H;/q;;;;+3/p-3
|
| Chemical Name |
iron(3+);2,12,13,15,17,18,20,23-octaethyl-21H-porphyrin;trichloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6024 mL | 8.0121 mL | 16.0241 mL | |
| 5 mM | 0.3205 mL | 1.6024 mL | 3.2048 mL | |
| 10 mM | 0.1602 mL | 0.8012 mL | 1.6024 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
